Trial Profile
A Phase 2 Randomized Study of LY2541546 Versus Placebo in Postmenopausal Women With Low Bone Mineral Density: An Evaluation of the Dose Response Relationship Using Bone Mineral Density.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Blosozumab (Primary)
- Indications Bone resorption; Postmenopausal osteoporosis
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 29 Mar 2015 Efficacy results related to baseline demographics presented at the 2015 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases.
- 05 Oct 2013 Spine and hip strength results (n=42) presented at the 35th Annual Meeting of the American Society for Bone and Mineral Research.
- 01 Feb 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.